Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 156 participants.

Also called NCT06218342

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 156 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06218342
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06218342. Randomized; no masking; primary purpose treatment. Start 2024-02-15 (anticipated); primary completion 2025-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease
Condition
Non-Alcoholic Fatty Liver Disease
Intervention (Drug)
Henagliflozin
Intervention (Other)
Background medication
Lead sponsor
Sir Run Run Shaw Hospital (class: other)

Record details

Record id
cardio:ct-nct06218342
Content hash
b71d122dba44a5ed4674a6b9ca662a444876a51efd6a48e7dc809341efa28571